<a href="https://www.fiercebiotech.com/biotech/erasca-hits-home-run-cancer-data-suffers-42-stock-drop" hreflang="en">Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death</a>
Erasca reported promising phase 1 data for its pan-RAS drug ERAS-0015, showing a 40% response rate in pancreatic cancer patients, but the stock plummeted 46% following a patient death attributed to treatment complications. Despite the positive efficacy claims, concerns over safety and a legal threat from competitor Revolution Medicines have overshadowed the results.
Erasca's recent phase 1 trial results for its pan-RAS drug, ERAS-0015, demonstrated promising efficacy, showing a 40% response rate in KRAS G12X-mutated pancreatic cancer and 62% in non-small cell lung cancer, outperforming rival daraxonrasib. However, the stock faced a significant drop due to a patient's death, highlighting the importance of monitoring and managing adverse events even when clinical data is strong. This scenario underscores the critical balance between efficacy and safety in biotech investments, especially in competitive oncology markets.